Mutational spectrum
The sitosterolaemia genes ABCG5 (NM_022436.2) and ABCG8 (NM_022437.2) lie 'head to head' on chromosome 2. 1-3 They each contain 13 exons and encode a half-transporter (sterolin-1 and sterolin-2, respectively), with the C-terminus only containing 6 of the usual 12 transmembrane domains of the other ABC transporters. 3 Together they form a heterodimeric transporter responsible for sterol trafficking in the liver and intestine. Loss-of-function mutations associated with sitosterolaemia have been described throughout the ABCG5 and ABCG8 genes.
Analytical methods
Sequencing (Sanger or NGS). NGS approaches include using exome analysis or as part of a hypercholesterolaemia/cardiac gene panel.
Analytical validation
Where a mutation(s) can be identified using sequencing, the test is repeated from a fresh dilution of DNA for confirmation. When heterozygosity for two mutations is found, testing of the patient's parents is recommended, to confirm that the two mutations are present in trans (that is, on opposite chromosomes).
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) If known to be variable between ethnic groups, please report:
No published data are available on the prevalence of sitosterolaemia, an autosomal recessive disorder, although the condition appears to be mainly owing to ABCG8 mutations in Caucasians, whereas in Chinese, Japanese and Indian patients with sitosterolaemia (20% of known cases), it is mainly owing to ABCG5 mutations. 4 On the basis of allele frequencies of loss-of-function variants (frameshift, nonsense and splicing only; not missense) in the ExAC database, sitosterolaemia has a global prevalence of at least 1 in 2.6 million for ABCG5 and 1 in 360 000 for ABCG8; the most common loss-of-function variant appears to be ABCG8 c.1083G4A (p.(Trp361Ter)) (Exome Aggregation Consortium; http://exac.broadinstitute.org/)
Diagnostic setting

Yes
No.
Comment: Use of genetic testing is essentially limited to confirmatory diagnosis in a subject suspected to be affected, rather than other applications such as predictive testing or prenatal diagnosis. 
TEST CHARACTERISTICS
Analytical specificity (proportion of negative tests if the genotype is not present)
Approximately 100%.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
Sitosterolaemia is a phenotypically heterogeneous disorder that is clinically characterised by increased plasma concentrations of plant sterols, xanthomas, arthralgia and premature atherosclerotic cardiovascular disease. 5, 6 In addition, some patients can present with haematological abnormalities including macrothrombocytopenia, stomatocytes, haemolytic anaemia and splenomegaly. 7, 8 Very rare patients can present primarily with elevated plasma levels of lowdensity lipoprotein cholesterol and cutaneous xanthomas, expressing a phenotype that resembles heterozygous familial hypercholesterolaemia (FH), 9 and in severe cases, resembling homozygous FH, with coronary disease in childhood and adolescence. 10, 11 The condition should be considered even when consumption of plant sterols has not commenced, as phytosterols can be found in breast milk. 12 
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
Positive clinical predictive value (life-time risk of developing the disease if the test is positive)
100%.
Negative clinical predictive value (probability of not developing the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: 100%. Index case in that family had not been tested: Patients with sitosterolaemia can be clinically differentiated from patients with other childhood xanthomatoses, such as FH, by the inheritance pattern, or cerebrotendinous xanthomatosis, by the absence of neurological involvement or cataracts.
3. CLINICAL UTILITY 3.1 (Differential) diagnostics: The tested person is clinically affected (To be answered if in 1.9 'A' was marked).
Sitosterolaemia should be considered in the differential diagnosis of severe hypercholesterolaemia, including apparent homozygous FH. 3.1.2 Describe the burden of alternative diagnostic methods to the patient Very low. Patients with sitosterolaemia exhibit generalised hyperabsorption of dietary sterols including cholesterol, shellfish sterols and plant sterols (sitosterol, stigmasterol and campesterol), which, combined with impaired biliary excretion, leads to markedly elevated plasma levels of these plant sterols; 430-fold, with sitosterol being the most abundant species. 4, 13 High levels of plant sterols in plasma are considered pathognomonic for sitosterolaemia, although elevations in plasma plant sterols may also be seen in primary biliary cirrhosis. 14 Cholesterol comprises only~80% of the total plasma sterols in patients with sitosterolaemia. Some obligate heterozygotes have mildly increased plant sterol levels. 15, 16 Mass spectrometry (GC and LC) plant sterol analysis of plasma is only available in specialist laboratories.
Can a diagnosis be made other than through a genetic test?
3.1.3 How is the cost-effectiveness of alternative diagnostic methods to be judged? Not applicable.
Will disease management be influenced by the result of a genetic test?
No □ Yes ⊠
Therapy (please describe)
A low plant sterol diet (avoidance of vegetable oils, margarine, nuts, seeds, avocados, chocolate), including restriction of algae-derived plant sterols found in shellfish and seaweed, can decrease plasma plant sterols levels, however, this is only partially effective as plant sterols are found in all plant-based foods. Ezetimibe (10 mg per day) is the pharmacotherapeutic agent of choice for the treatment of sitosterolaemia. Ezetimibe, which binds to the Niemann-Pick C1-like 1 sterol transporter in the proximal intestine, blocks the uptake of sterols leading to marked reductions in plasma sterol concentrations. Bile acid binding resins such as cholestyramine may be considered for use in those patients who fail to fully respond to ezetimibe, however, gastrointestinal side effects can limit its tolerability. Statins are minimally effective as HMG-CoA reductase is already maximally inhibited in patients with sitosterolaemia. [17] [18] [19] [20] Prognosis (please describe)
Patients with sitosterolaemia show marked phenotypic heterogeneity. The patient's phenotype and prognosis depends on their age at diagnosis, the proportion of sterols they absorb (environmental and genetic variation dependent), and when they commenced a plant sterolrestricted diet and pharmacotherapy. Early treatment with ezetimibe leads to regression of xanthomas and atherosclerotic cardiovascular disease in patients with sitosterolaemia. 21 It has also been shown to normalise most haematological abnormalities. 22 
Management (please describe)
The clinical follow-up and management of sitosterolaemia focuses on detecting and preventing complications, and monitoring compliance with diet and pharmacotherapy.
Predictive Setting:
The tested person is clinically unaffected, but carries an increased risk based on family history (To be answered if in 1.9 'B' was marked).
